Interpretation of Clinical Practice Guidelines for Management of Kidney Injury During Anticancer Drug Therapy 2022 (Ⅴ): dose adjustment of anticancer drug therapy in patients with impaired kidney function (Part 2)
10.3760/cma.j.cn114015-20240628-00495
- VernacularTitle:《抗肿瘤药物治疗期间肾损伤管理临床实践指南（2022）》解读（五）：肾损伤患者抗肿瘤药物的剂量调整（第2部分）
- Author:
Yue YIN
1
;
Yanhua ZHANG
1
Author Information
1. 北京大学肿瘤医院暨北京市肿瘤防治研究所药剂科，恶性肿瘤发病机制及转化研究教育部重点实验室，北京 100142
- Publication Type:Journal Article
- Keywords:
Antineoplastic agents;
Chronic kidney disease;
Renal insufficiency;
Drug dose adjustment;
Guideline;
Interpretation
- From:
Adverse Drug Reactions Journal
2024;26(9):513-518
- CountryChina
- Language:Chinese
-
Abstract:
Drugs or their metabolites may accumulate in the body due to the decline of renal excretion function in cancer patients with renal insufficiency. Therefore, adjusting the treatment scheme and drug dose according to the patient's renal function is an important part of anticancer treatment for these patients. The Japanese Society of Nephrology, Japan Society of Clinical Oncology, Japanese Society of Medical Oncology, and Japanese Society of Nephrology and Pharmacotherapy have jointly formulated Clinical Practice Guidelines for Management of Kidney Injury During Anticancer Drug Therapy 2022, and specifically discusses the dose adjustment of anticancer drug treatment for patients with renal injury in the second chapter. This article focuses on the interpretation of the application and dose adjustment of antifolate agents, BCR-ABL1 tyrosine kinase inhibitors, epithelial growth factor receptor tyrosine kinase inhibitors, antibody molecularly targeted agents and tumor adjuvant therapy drugs such as bone-modifying agents in patients with renal injury in this chapter.
